Insiders At 4D Molecular Therapeutics Sold US$757k In Stock, Alluding To Potential Weakness
This article analyzes recent insider selling at 4D Molecular Therapeutics, where insiders sold US$757k worth of stock over the last year. While this isn't necessarily a strong bearish signal on its own, it suggests that insiders might view the stock as fully valued given the lack of significant insider buying during the same period. The analysis encourages investors to consider multiple factors beyond just insider transactions when evaluating the company.
4D Molecular Therapeutics Insiders Sold US$757k Of Shares Suggesting Hesitancy
Over the past year, insiders at 4D Molecular Therapeutics (NASDAQ:FDMT) have sold US$757k worth of shares, primarily led by Co-Founder David Kirn. The sales, particularly one at US$12.87 per share (below the current US$14.49), suggest potential hesitancy from insiders, although selling can have various motivations. Despite the selling, insiders still own 2.8% of the company, valued at approximately US$23 million, which indicates some alignment with shareholder interests.
FDMT Maintains by B of A Securities -- Price Target Raised to $3
B of A Securities maintained its rating for 4D Molecular Therapeutics (FDMT) and raised its price target to $33.00, indicating optimism about the company's prospects. Despite being 55.6% undervalued according to GF Value, FDMT shows moderate overall performance with weaknesses in profitability and growth, and has recently experienced significant insider selling.
4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway
4D Molecular Therapeutics (FDMT) is reaffirmed as a 'Buy' due to the progress of its gene therapy, 4D-150, in phase 3 trials for wet AMD and diabetic macular edema (DME). The company anticipates topline data for its wet AMD studies in Q2 and H2 2027, with previous data indicating a significant reduction in injection burden for both conditions. 4D Molecular is financially stable through 2028 and has several upcoming catalysts, including updates on its cystic fibrosis program.
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
4D Molecular Therapeutics has advanced its 4D-150 treatment into Phase 3 development for diabetic macular edema (DME), marking its second large market retina indication. The company announced the enrollment of the first patients in the 4SIGHT global Phase 3 trial and presented updated 2-year data from the SPECTRA Part 1 trial, showing a favorable safety profile, durable vision and anatomic improvements, and significant treatment burden reduction. This move aims to establish 4D-150 as a continuous backbone therapy for VEGF-driven retinal diseases, potentially transforming DME treatment with a single intravitreal injection.
4D Molecular Therapeutics Begins Phase 3 4D-150 DME Trial
4D Molecular Therapeutics has initiated its global 4SIGHT Phase 3 trial for 4D-150 to treat diabetic macular edema, enrolling the first patients. The trial aims to demonstrate non-inferior vision outcomes with fewer aflibercept injections. Concurrently, two-year SPECTRA data showed 4D-150 was well tolerated, improved vision, reduced retinal thickness, and significantly cut projected injection burden by 61% to 75%.
A 9-person study reported 61% lower injection burden with 4D-150 versus a 13-shot projection.
4D Molecular Therapeutics (FDMT) has initiated its 514-patient 4SIGHT Phase 3 trial for 4D-150 in diabetic macular edema (DME), following positive two-year results from the earlier SPECTRA trial. In the SPECTRA trial, a nine-patient group receiving the Phase 3 dose of 4D-150 experienced a 61% reduction in supplemental injections compared to projected aflibercept injections. The company also announced alignment with the FDA and EMA for potential regulatory filings using a single DME Phase 3 trial, combined with data from other trials.
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
4D Molecular Therapeutics (4DMT) has initiated the 4SIGHT Phase 3 clinical trial for its product candidate 4D-150 in patients with diabetic macular edema (DME), marking its second Phase 3 program for a major retinal disease. The company reported positive 2-year data from the SPECTRA Part 1 trial, showing 4D-150 was well-tolerated with durable vision and anatomic improvements, and a significant reduction in treatment burden for DME patients. 4D-150, which uses an AAV vector to deliver anti-VEGF biologics, aims to provide long-lasting treatment with a single intravitreal injection, potentially transforming care for wet AMD and DME.
4D Molecular Therapeutics Initiates Patient Enrollment in Phase 3 4SIGHT Trial for Diabetic Macular Edema
4D Molecular Therapeutics has begun patient enrollment for its Phase 3 4SIGHT clinical trial, evaluating 4D-150 for diabetic macular edema (DME). The company also released positive two-year data from the SPECTRA clinical trial, showing a favorable safety profile and significant reduction in treatment burden for 4D-150. This development marks a key step towards regulatory submissions, with FDA RMAT designation already granted for 4D-150 in DME.
4D Molecular Therapeutics Begins Phase 3 Trial of 4D-150 in Diabetic Macular Edema
4D Molecular Therapeutics has initiated a Phase 3 trial for its drug candidate, 4D-150, aimed at treating Diabetic Macular Edema. The company has successfully enrolled the first patients for this pivotal study. Access to the full details of this development requires a premium subscription to MT Newswires.
Form 4 4D Molecular Therapeutics Inc For: 22 September By Investing.com
This article from Investing.com announces the filing of a Form 4 for 4D Molecular Therapeutics Inc. on September 22nd. The content appears to be a placeholder or a very brief report, as it mainly consists of boilerplate text and navigation elements common to financial news sites. The Form 4 filing typically reports changes in beneficial ownership of a company's securities by insiders.
4D Molecular (FDMT) legal chief exercises options, then sells 1,635 shares
Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics (FDMT), exercised options for 1,635 shares at $4.14 per share and simultaneously sold them for $13.65 per share on September 16, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Bizily retains a substantial option position of 58,066 shares, which continue to vest monthly.
Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock By Investing.com
Scott Bizily, Chief Legal Officer at 4D Molecular Therapeutics (NASDAQ:FDMT), sold 1,635 shares of company stock for $22,317 on September 16, 2026, as part of a pre-arranged trading plan. This sale followed the exercise of stock options and occurred while the stock has seen a significant surge over the past year. The company has recently received positive analyst upgrades and maintained Buy ratings due to its advancements in gene therapy treatments.
4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing
David Kirn, Director, President, and Chief Executive Officer of 4D Molecular Therapeutics, sold 58,333 shares of the company's stock on September 14, 2026. This transaction amounted to $811,004. The full details of this insider sale are available through a premium subscription to MT Newswires.
4D Molecular Therapeutics (FDMT) CEO sells 58K shares under preset plan
The CEO and director of 4D Molecular Therapeutics, David Kirn, sold 58,333 shares of common stock on September 14, 2026, at a weighted average price of $13.903 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted on January 9, 2026, leaving him with 767,486 shares directly. The sale had a moderate filing impact and a negative sentiment, according to the analysis.
Kirn David Executes Open-Market Sale of 58,333 Shares in 4D Molecular Therapeutics
Kirn David sold 58,333 shares of 4D Molecular Therapeutics (FDM) on September 14, 2026, at a price of $13.90 per share. This open-market sale represented approximately 7.1% of his previous holdings in the company. Following the transaction, Kirn David retained 767,486 shares of 4D Molecular Therapeutics.
4D molecular therapeutics CEO Kirn sells $811,003 in stock
David Kirn, CEO of 4D Molecular Therapeutics (NASDAQ:FDMT), sold 58,333 shares worth $811,003 on September 14, 2026, executed via a pre-arranged 10b5-1 trading plan. This sale follows a significant 106% stock return over the past year. Despite the sale, the stock is considered undervalued, and the company has received multiple analyst upgrades due to promising gene therapy developments, particularly for its 4D-150 treatment.
4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing
An insider at 4D Molecular Therapeutics (FDMT) recently sold shares valued at $811,004, as disclosed in a U.S. Securities and Exchange Commission (SEC) filing. The article highlights other recent news for the biotechnology company, including presentations at healthcare conferences and analyst rating changes. 4D Molecular Therapeutics is focused on developing durable, disease-targeted therapeutics, with its lead product candidate, 4D-150, in Phase III development for wet age-related macular degeneration.
Cantor Fitzgerald upgrades 4D Molecular stock rating on gene therapy outlook
Cantor Fitzgerald upgraded 4D Molecular Therapeutics (FDMT) to Overweight from Neutral, setting a price target of $20.00, representing a 52% upside. The upgrade is based on confidence in their intravitreal VEGF gene therapy 4D-150 for wet age-related macular degeneration and diabetic macular edema, following recent mixed results from competitors. The company also recently announced positive Phase 2b data, completed enrollment for a pivotal Phase 3 trial, and elected new board members.
4D Molecular Therapeutics Grants RSUs to Seven New Non-Executive Employees
4D Molecular Therapeutics granted 96,000 Restricted Stock Units (RSUs) to seven new non-executive employees on September 8, 2026, as part of its 2025 Employment Inducement Award Plan to attract new talent. The company, which specializes in late-stage biotechnology, is developing treatments for blinding retinal vascular diseases (4D-150, in Phase 3 trials) and cystic fibrosis (4D-710). All product candidates are still in clinical or preclinical stages and have not yet received regulatory approval.
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176
Scott Bizily, Chief Legal Officer at 4D Molecular Therapeutics (NASDAQ:FDMT), sold shares worth $8,176 after exercising stock options. These transactions were executed under a pre-arranged 10b5-1 trading plan. The company is also advancing its pivotal Phase 3 trials for the 4D-150 gene therapy and has received reiterated Buy ratings from analysts.
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics (4DMT) announced its participation in three upcoming investor conferences in September 2026: the Wells Fargo 2026 Healthcare Conference, the 2026 Cantor Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference. Management will present and engage in one-on-one meetings, with a fireside chat scheduled for the Cantor and Morgan Stanley events. Webcasts of these presentations will be archived on the company's investor relations website for one year.
4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7% - Here's What Happened
Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) dropped 3.7% on Friday, trading at around $15.50 on lower-than-average volume. Despite a "Moderate Buy" consensus rating and a $29.62 average price target from analysts, the company reported a quarterly loss of $1.04 per share, missing estimates, though revenue exceeded expectations. Insider selling also occurred, with 200,496 shares sold for approximately $2.24 million in the last quarter.
4D Molecular Therapeutics (NASDAQ: FDMT) CEO sells 69K shares in preset plan
David Kirn, CEO of 4D Molecular Therapeutics (NASDAQ: FDMT), exercised stock options for 50,000 shares at $4.14 each and subsequently sold 69,076 common shares in open-market transactions on August 19, 2026. The sales, totaling approximately $1.09 million gross proceeds, were conducted under a Rule 10b5-1 trading plan established on January 9, 2026. After these transactions, Kirn retains 217,500 stock options and 825,819 common shares.
David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale
David Kirn, an officer at 4D Molecular Therapeutics, Inc. (FDMT), plans to sell 69,076 shares of Class A Common Stock valued at approximately $1.16 million through Goldman Sachs & Co. LLC. This sale is part of a Rule 10b5-1(c) selling plan initiated on January 9, 2026. The filing indicates previous sales by Kirn and details how the shares were acquired, some through private transactions and others via stock options.
4D Molecular Therapeutics(FDMT) Stock Options Chain | Quotes & News
This document appears to be a stub or an empty page for 4D Molecular Therapeutics (FDMT) stock options chain, quotes, and news. It indicates a lack of detailed content, suggesting it might be a placeholder.
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock
4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, sold company shares worth $39,567 after exercising stock options. The company's stock has performed well, gaining over 100% in the past year and trading near its 52-week high. These transactions were executed under a pre-arranged 10b5-1 trading plan, and the company continues to receive favorable analyst ratings following positive clinical trial data and strong corporate developments.
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month High - Time to Buy?
4D Molecular Therapeutics (NASDAQ:FDMT) recently hit a new 52-week high of $15.03, closing at $14.55, but the company remains unprofitable with a negative EPS. While analyst sentiment is generally positive, with a "Moderate Buy" consensus and an average price target of $29.62, some insiders have been selling shares. Hedge funds have also been adjusting their positions, with institutional investors owning 99.27% of the stock.
146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC
Perigon Wealth Management LLC has purchased 146,185 shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) for approximately $1.94 million during the second quarter. Institutional investors and hedge funds collectively own 99.27% of the company, with various firms increasing their stakes. The company's stock is trading up by 19.4% and has a "Moderate Buy" consensus rating from analysts, despite an insider selling off shares and the company reporting an EPS loss.
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock
Scott Bizily, Chief Legal Officer at 4D Molecular Therapeutics, sold shares worth $39,567 on August 13 and 17, 2026, after exercising stock options. The company's stock has seen over 100% gain in the past year, trading near its 52-week high. These transactions were executed under a pre-arranged 10b5-1 trading plan, and the company has also received positive analyst ratings and completed significant trial milestones.
Scott Bizily plans new 4D Molecular (NASDAQ: FDMT) sale after 10b5-1 stock trades
Scott Bizily plans to sell 6,540 shares of 4D Molecular Therapeutics (NASDAQ: FDMT) on August 17, 2026, following the exercise of stock options. This transaction, processed through Morgan Stanley Smith Barney LLC, has an associated value of $79,722.60. The filing also details three previous programmed sales by Bizily under a 10b5-1 trading plan that occurred between June and August 2026.
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares
Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics (FDMT), sold 3,270 shares of common stock after exercising options. The transactions occurred on August 13 and August 17, 2026, with sales at $12.00 and $12.20 per share, respectively, and were executed under a Rule 10b5-1 trading plan adopted in January 2026. Bizily's options were exercised at $4.14 per share, and the total pre-tax spread from these transactions was approximately $26,000.
A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $35 to $36
This article provides a brief overview of recent analyst ratings for 4D Molecular Therapeutics (FDMT.US), highlighting that analysts have set price targets ranging from $35 to $36. The information suggests a positive outlook from financial experts regarding the company's stock performance.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 35,200 Restricted Stock Units (RSUs) to five new non-executive employees on August 11, 2026. These grants were made under the company’s 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 35,200 Restricted Stock Units (RSUs) to five new non-executive employees on August 11, 2026. These grants were made under the Company’s 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
4DMT Announces New Employment Inducement Grants
4DMT announced new employment inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). The grants, consisting of stock options and restricted stock units, were made to 11 new employees on August 12, 2026. The options have a 10-year term and vest over four years, while the RSUs vest over three or four years.
H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com
H.C. Wainwright has reiterated a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target, citing positive two-year data from the Phase 2b PRISM trial for its 4D-150 gene therapy. The company has also completed enrollment for its pivotal Phase 3 4FRONT-2 global trial and 4FRONT-1 North American trial, with topline data expected in Q2 and H2 2027, respectively. Shares have surged 64% over the past year, though the company is noted for its volatility and cash burn.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 35,200 Restricted Stock Units (RSUs) to five new non-executive employees on August 11, 2026. These grants were made under the company's 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on advancing therapeutics for diseases like wet age-related macular degeneration and cystic fibrosis.
H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com
H.C. Wainwright has reiterated a Buy rating and a $36.00 price target for 4D Molecular Therapeutics (NASDAQ:FDMT), citing positive two-year data from its Phase 2b PRISM trial for the gene therapy 4D-150. The company is progressing with its pivotal Phase 3 4FRONT-1 and 4FRONT-2 trials, with topline data expected in Q2 and H2 2027, respectively. Despite stock volatility and cash burn, analysts view 4D-150 as a potential breakthrough in retina treatment.
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics (4DMT) reported its second-quarter 2026 financial results, highlighting significant operational achievements including the completion of enrollment for its 4D-150 4FRONT-2 wet AMD Phase 3 trial and positive 2-year data from the PRISM Phase 2b trial. The company also announced a new strategic credit facility for up to $200 million, an upcoming Investor Day, and an estimated cash runway into the second half of 2028.
FDMT (NASDAQ: FDMT) stockholder schedules 1,635-share sale after option exercise
A stockholder of 4D Molecular Therapeutics, Inc. (FDMT) has filed to sell 1,635 common shares on NASDAQ, to be issued through the exercise of stock options for cash on August 13, 2026. This filing also discloses previous Rule 10b5-1 plan sales by Scott Bizily in the past three months, including sales of 6,566 shares for $91,924.00 on June 30, 2026, and 9,810 shares for $117,720.00 on June 23, 2026. The transaction is being handled by Morgan Stanley Smith Barney LLC’s Executive Financial Services.
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics (4DMT) reported its Q2 2026 financial results, highlighting significant progress in its clinical programs for wet AMD and DME, including completed enrollment for two Phase 3 trials for 4D-150 and strong two-year data from its PRISM Phase 2b study. The company also secured a $200 million credit facility and expects its current cash position to fund operations into the second half of 2028. Upcoming milestones include further Phase 3 initiations and an Investor Day in October.
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) reported a Q2 loss of $1.04 per share, matching Zacks Consensus Estimate, but surpassed revenue estimates significantly with $3.78 million, beating expectations by 142.37%. The company's stock has performed well year-to-date, rising 58.3% against the S&P 500's 13.2% gain, and currently holds a Zacks Rank #3 (Hold).
Dimensional Fund Advisors LP Purchases 227,982 Shares of 4D Molecular Therapeutics, Inc. $FDMT
Dimensional Fund Advisors LP has increased its stake in 4D Molecular Therapeutics (NASDAQ:FDMT) by 77.3%, purchasing an additional 227,982 shares to bring its total ownership to 522,823 shares, representing 1.0% of the company. Institutional investors now own 99.27% of the stock, while company insiders have recently sold a significant number of shares. Analysts currently give FDMT a "Moderate Buy" rating with a consensus price target of $29.75.
4D Molecular Therapeutics Inc (FDMT) Stock News Today
This article provides current stock information for 4D Molecular Therapeutics Inc (FDMT), noting its recent price dip. It states that more news regarding FDMT's earnings, analyst ratings, and key developments will be available soon. The page serves as a hub for investors to track FDMT stock performance and related updates.
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
4D Molecular Therapeutics Inc (FDMT) is projected to report a loss of $1.02 per share in its upcoming earnings announcement. This information comes from a Refinitiv earnings preview. The article provides a brief outlook on the company's expected financial performance.
4D Molecular Therapeutics, Inc. (FDMT) Stock Price, News, Quote & History
This Yahoo Finance page provides comprehensive financial information for 4D Molecular Therapeutics, Inc. (FDMT), a late-stage biotechnology company. It includes real-time stock price, historical data, performance metrics against the S&P 500, analyst ratings,
4D Molecular Therapeutics, Inc. (FDMT) insider sells 26,842 shares under plan
David Kirn, a director and officer at 4D Molecular Therapeutics, Inc. (FDMT), sold 26,842 shares of common stock on August 4, 2026, at a weighted average price of $10.2301 per share. This transaction was conducted under a 10b5-1 trading plan established on January 9, 2026. Following the sale, Kirn directly holds 844,895 common shares in the company.
David Kirn Sells 12,415 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock
David Kirn, an insider at 4D Molecular Therapeutics (NASDAQ:FDMT), recently sold 12,415 shares of the company's stock for a total value of $124,770.75, reducing his position by 1.40%. This sale follows several other transactions by Kirn in recent months. Despite missing quarterly EPS expectations, the company's revenue exceeded estimates, and institutional investors hold a significant portion of the stock, with analysts maintaining a "Moderate Buy" rating.
Ken Fisher's 4D Molecular Therapeutics Inc(FDMT) Holding History
This article details Ken Fisher's investment in 4D Molecular Therapeutics Inc (FDMT), held through Fisher Asset Management, LLC. As of June 30, 2026, he owns 65,751 shares valued at $874,490, representing 0% of his portfolio. Fisher has made one purchase of FDMT at an average price of $9.74, resulting in an estimated gain of 10.52% on his holdings.
